Details of the Drug-Related molecule(s) Interaction Atlas

FR-173657 Drug Info

FK-3657; FR-173657; FR173657; FR 173657; CHEMBL130517; XCKWRUGRUFVXGC-NTEUORMPSA-N; AC1NSK08; GTPL674; 167838-64-4; SCHEMBL1559539; SCHEMBL3718364; BDBM50067301; FK 3657; L015626; 3-(6-acetamidopyridin-3-yl)-N-(2-((2,4-dichloro-3-((2-methylquinolin-8-yloxy)methyl)phenyl)(methyl)amino)-2-oxoethyl)acrylamide; (E)-3-(6-acetamidopyridin-3-yl)-N-[2-[2,4-dichloro-N-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide

Cross-matching ID

PubChem CID

5311108

CAS Number

CAS 167838-64-4

TTD Drug ID

DM37OS4

General Information of Drug (ID: DM37OS4)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting B2 bradykinin receptor (BDKRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Icatibant	DMQPTOZ	Hereditary angioedema	4A00.14	Approved	[2]
Fasitibant chloride	DM563NC	Osteoarthritis	FA00-FA05	Phase 2	[3]
DELTIBANT	DM5CB8U	Sepsis	1G40-1G41	Phase 2	[4]
Anatibant	DMG7IEN	Traumatic brain injury	NA07.Z	Phase 2	[5]
DM199	DM0157T	Cerebral ischemia	8B11	Phase 2	[6]
BRADYKININ	DM4R6UV	N. A.	N. A.	Phase 1	[7]
NPC-567	DMAVZ1F	Rhinitis	FA20	Discontinued in Phase 2	[8]
Labradimil	DMSFL76	Brain cancer	2A00	Discontinued in Phase 2	[9]
NPC-17731	DMGVIZY	Asthma	CA23	Terminated	[10]
JSM-10292	DMU5TGC	Pain	MG30-MG3Z	Terminated	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B2 bradykinin receptor (BDKRB2)	TTGY8IW	BKRB2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Novel small molecule bradykinin B2 receptor antagonists. J Med Chem. 2009 Jul 23;52(14):4370-9.
2	Bradykinin receptor antagonists--a review of the patent literature 2005-2008. Expert Opin Ther Pat. 2009 Jul;19(7):919-41.
3	Fasitibant chloride, a kinin B receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br J Pharmacol. 2012 Jun;166(4):1403-10.
4	CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. 1992;38 ( Pt 3):413-20.
5	Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med. 2009 Jul;37(7):2228-34.
6	Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors. Pharmacol Res Perspect. 2015 Mar;3(2):e00119.
7	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
8	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
9	Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med. 2009 May 13;7:33.
10	Antinociceptive profile of the pseudopeptide B2 bradykinin receptor antagonist NPC 18688 in mice. Br J Pharmacol. 1996 Feb;117(3):552-558.
11	Binding characteristics of [3H]-JSM10292: a new cell membrane-permeant non-peptide bradykinin B2 receptor antagonist. Br J Pharmacol. 2012 Oct;167(4):839-53.